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correlate with cognitive impairment in
Parkinson’s diseaseWe read the recent findings by Winston et al. [1] with
great interest. The quantification of extracellular vesicles
(including exosomes) has presented several challenges
despite the availability of a number biophysical techniques,
including nanoparticle tracking analysis (NanoSight, Ltd.)
and tunable resistive pulse sensing (Izon Science, Ltd.)
[2]. These challenges are mainly due to the small size and
polydispersity of exosomes and the lack of a standardized
methodology for measuring exosomes which allows
results from different days, users, and instruments to be
compared [3].
We recently attempted to characterize exosomes in a
small group of Parkinson’s disease (PD) patients (detailed
methodology is described elsewhere [2,3]). The patients
enrolled in our study were administered the Montreal
Cognitive Assessment (MoCA) before obtaining the
biofluid samples. The MoCA has recently been validated
by our group as superior to the mini mental state
examination in assessing cognitive impairment in PD
patients [4]. Suggested cutoff scores were PD-normal cogni-
tion (PD-N) 26, PD-mild cognitive impairment (PD-MCI)
5 21–25, and PD-dementia (PD-D)  20.
We recruited 11 PD patients, regardless of cognitive func-
tion. The patients, all of whomwere male, had a mean age of
666 11.5 years, mean disease duration of 70 6 30 months,
and mean MoCA scores of 25.66 2.6 points. Paired plasma
samples, 28 days apart, were obtained from all patients
except two (total samples 5 20).
Analysis of exosome concentration in plasma revealed an
unexpected pattern. Although a wide variation among our
patients (mean, 19.4 6 21.7 ! 109 exosomes/mL; size
range, 150–300 nm) was observed, three patients in partic-
ular (see Fig. 1) exhibited plasma exosome concentrations
that were 10- to 20-fold higher than the rest of the sample
(mean, 43.5 vs. 7.4 ! 109 exosomes/mL, respectively).
This discrepancy was repeatable in plasma samples
collected 28 days later (mean, 44.5 vs. 5.4 ! 109 exo-
somes/mL). Incidentally, these three patients had lower*Corresponding author. Tel.: 16421750015; Fax: 16433646080.
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).MoCA scores compared with the other patients (mean,
22.7 vs. 26.9, respectively).
The correlation we describe here is intriguing but insuf-
ficiently powered to draw definitive answers. In a recent
study [5], 37 PD patients were found to have significantly
higher concentrations of cerebrospinal fluid (CSF) exo-
somes compared with patients with dementia with Lewy
bodies, progressive supranuclear palsy, and polyneurop-
athy. The study, however, did not stratify PD patients by
cognitive function, and only CSF samples were analyzed.
Cognitive correlates using plasma, much more easily
accessible than CSF, may be more appealing in clinical ap-
plications.
Ridder et al [6] have recently reported increased
transfer of genetic material, via exosomes, between mu-
rine hematopoietic cells and Purkinje neurons in states of
neuroinflammation. This could afford a potential expla-
nation for the observed higher exosome concentration
in PD-MCI, reflecting a more severe and/or underlying
neuroinflammatory process compared with PD-N. To
provide more definitive conclusions, however, larger
studies that examine CSF and plasma concentrations of
exosomes in PD-N, PD-MCI, and PD-D patients are
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Fig. 1. The relative concentrations of exosomes detected in 11 participants are shown, with samples from participants 1, 3, and 10 exhibiting the highest con-
centrations.
Y. Alamri et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 4 (2016) 107-108108References
[1] Winston CN, Goetzl EJ, Akers JC, Carter BS, Rockenstein EM,
Galasko D, et al. Prediction of conversion from mild cognitive impair-
ment to dementia with neuronally derived blood exosome protein pro-
file. Alzheimers Dement (Amst) 2016;3:63–72.
[2] Vogel R, Willmott G, Kozak D, Roberts GS, Anderson W,
Groenewegen L, et al. Quantitative Sizing of Nano/Microparticles
with a Tunable Elastomeric Pore Sensor. Anal Chem 2011;
83:3499–506.
[3] Roberts GS, Yu S, Zeng Q, Chan LC, Anderson W, Colby AH, et al.
Tunable pores for measuring concentrations of synthetic and biological
nanoparticle dispersions. Biosens Bioelectron 2012;31:17–25.[4] Dalrymple-Alford JC, MacAskill MR, Nakas CT, Livingston L,
Graham C, Crucian GP, et al. The MoCA: well-suited screen for cogni-
tive impairment in Parkinson disease. Neurology 2010;75:1717–25.
[5] Stuendl A, Kunadt M, Kruse N, Bartels C, Moebius W, Danzer KM,
et al. Induction of alpha-synuclein aggregate formation by CSF exo-
somes from patients with Parkinson’s disease and dementia with
Lewy bodies. Brain 2016;139(Pt 2):481–94.
[6] Ridder K, Keller S, Dams M, Rupp AK, Schlaudraff J, Del Turco D,
et al. Extracellular vesicle-mediated transfer of genetic information be-
tween the hematopoietic system and the brain in response to inflamma-
tion. PLoS Biol 2014;12:e1001874.
http://dx.doi.org/10.1016/j.dadm.2016.08.002
